Importantly, we uncovered that HDGF down-regulation could abate IGF2BP2/TUG1-mediated CRC cisplatin resistance through autophagy inhibition and suppress the profiles of DDX5 and β-catenin. This evidence concerns the gene IGF2BP2 and colorectal carcinoma.